News

Since its inception, the European Lead Factory (ELF) has been recruiting high quality drug discovery programmes from all over Europe. Over the past five years, the thorough recruitment and selection process has led to a balanced portfolio of innovative disease targets that have been screened against our unique compound library. We now have three successful ELF programmes in the field of CNS & Neurology available for partnering.

We are pleased to confirm that following the UK's exit from the European Union on 31 January, the European Lead Factory (ELF) will still be able to process the drug target proposals of UK researchers over the coming years.

Scientists from the Yarwood Lab and the European Screening Centre have jointly published on the discovery of a new class of EPAC activators. The study, which describes the identification, optimisation and characterisation of a new chemical class of selective agonists for EPAC1, is the result of another successful collaboration within the framework of the European Lead Factory (ELF).

This 30 January marks the inaugural World Neglected Tropical Diseases (NTD) Day, an initiative designed to draw attention to priority issues surrounding NTDs and the efforts being made to combat them. Falling on the anniversary of the landmark 2012 London Declaration on NTDs, which united partners in the drive for greater action on NTDs, the Day hopes to inspire further support for this cause.